Your browser is out-of-date!

Update your browser to view this website correctly.

Disclaimer
To continue, please select your country of domicile and investor type. Depending on your domicile and the investor type that you select, you will have full or restricted access to the information due to legal reasons.

Retail clients: according to Art. 4 Abs. 2 FinSA

Professional/Institutional investors: according to Art. 4 paragraph 3-5 and Art. 5 paragraph 1 and 3-4 FinSA and Art. 10 paragraph 3 and 3ter CISA in conjunction with Art. 6a CISO

Important

Principles 

By using the website www.bellevue.ch, you confirm that you have read, understood and accepted the general information provided by the Bellevue Group AG as well as these legal provisions. These may be subject to change and the use of the site may be restricted or terminated at any time without prior notice.

No recommendation and/or offer for subscription (or for purchase) and/or redemption (or for sale)

The information, products, data, services, tools and documents contained or described on this site ("website content") are for information purposes only and constitute neither an advertisement or recommendation nor an offer or solicitation (to buy) or redemption (sell) investment instruments, to effect any transaction or to enter into any legal relations.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.rlich sind.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.

In order to determine whether the investment in shares of a certain investment fund meets your specific requirements and matches your envisaged risks, we recommend that you contact an independent financial adviser. Furthermore, we recommend that you consult an independent tax adviser in order to obtain information on the tax regulations relating to a specific investment in your legal jurisdiction and with regard to your personal circumstances. In particular tax treatment depends on individual circumstances and may be subject to change.

As the funds are recognised (ie. registered) but not authorised in the UK, the UK Financial Services Authority's financial services compensation scheme does not apply to investments in the fund but the Financial Services Authority regulated firm approving this document for the purposes of UK regulation has taken reasonable steps to satisfy itself that Bellevue will deal in an honest and reliable way and is so satisfied.

Performance

Past performance is not an indication or guarantee of the future performance of the investment. The value of investments may be subject to fluctuations and, under certain circumstances, investors may not get back the full amount invested. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions and commissions and costs have a negative impact on performance. Changes in foreign-exchange rates may also cause the value of investments to go up or down.

Target group of the sites 

The sites are intended exclusively for use by legal entities and natural persons having their registered office or residing in countries in which the investment funds or the related subfunds or share classes of the Bellevue Group have been properly licensed or approved for public offer or sale in accordance with the applicable local legislation. The funds are currently registered for public distribution offer in the following countries: Luxembourg, Switzerland, Germany, Austria, Spain and Portugal. In all other countries, the funds may, if any, via "Private Placement" according to the local applicable laws.

It is explicitly stated, that alternative fund products are not allowed for public distribution in any country and that they may only and exclusively be solicited to institutional and qualified private investors according to the applicable local laws of each country.

The information and services provided on the sites are not intended for offer to or use by legal entities or natural persons in legal jurisdictions or countries in which the offer or use thereof would violate local legislation or legal provisions, or in which business units forming part of Bellevue Group would be subject to registration requirements in such jurisdictions or countries. Legal entities or natural persons to which such prohibitions apply must not access or use these sites.

The Bellevue funds have NOT been licensed for public offer or sale to the public in the United States in accordance with the US Investment Company Act of 1940 or the US Securities Act of 1933, or in Canada, Japan, Taiwan, Malaysia, Hong Kong or Israel in accordance with the laws in force in those countries. Therefore, particular importance is attached to ensuring that these sites are not intended for legal entities or natural persons, who have their registered office or who reside in such countries, their territories or dependencies or who, on account of their citizenship or similar status, are subject to the law of one of these countries.

Fund documents Luxembourg Fund

Bellevue SICAV: The Bellevue Funds (Lux) SICAV is admitted for public offering and distribution in Switzerland . Representative agent in Switzerland   Waystone Fund Services (Switzerland) SA, Avenue Villamont 17, CH-1005 Lausanne and paying agent in Switzerland: DZ PRIVATBANK (Schweiz) AG Münsterhof 12, PO Box, CH-8022 Zürich. Austria: Paying and information agent: Zeidler Legal Process Outsourcing Limited., 19-22 Lower Baggot Street, Dublin 2, D02 X658, Ireland. Germany: information agent: Zeidler Legal Process Outsourcing Limited., 19-22 Lower Baggot Street, Dublin 2, D02 X658, Ireland. Spain: The Bellevue Funds (Lux) SICAV is registered with the CNMV under the number 938. Paying and information agent: atl Capital, Calle de Montalbán 9, ES-28014 Madrid.  Prospectus, Key Investor Information Document (“KID”), the articles of association as well as the annual and semi - annual reports of the Bellevue Funds under Luxembourg law are available free of charge from the above mentioned representative, paying, facilities and information agents as well as from Bellevue Asset Management AG, Seestrasse 16 , CH - 8700 Kusnacht. 

Bellevue Asset Management (Deutschland) GmbH: You can obtain the sales prospectus, the annual reports and the german key investor information documents free of charge from Bellevue Asset Management (Deutschland) GmbH, and also from banks and financial advisers. Paying agent in Switzerland is DZ PRIVATBANK (Schweiz) AG, Münsterhof 12, PO Box, CH-8022 Zurich. The swiss agent is IPConcept (Schweiz) AG, In Gassen 6, PO Box, CH-8022 Zurich. In Switzerland you can obtain sales prospectus, the annual reports and the german key investor information documents free of charge from the agent and also from the paying agent. 

Fund documents Bellevue Entrepreneur Switzerland

Prospectus, Key Investor Information Document („KID“), fund contract as well as the annual and semi - annual reports of the Bellevue Fund under Swiss law are available free of charge from: Switzerland : PMG Fonds Management AG, Dammstrasse 23, 6300 Zug or Bellevue Asset Management AG, Seestrasse 16, CH - 8700 Kusnacht. 

Fund documents Bellevue Funds and Bellevue Healthcare Strategy

Prospectus, Key Investor Information Document („KID“), fund contract as well as the annual and semi - annual reports of the Bellevue Medtech and Services fund established under Swiss law in the category "Other Funds for Traditional Investments" are available free of charge from : Switzerland : Swisscanto Fondsleitung AG, Bahnhofstrasse 9 , CH - 8001 Zürich or Bellevue Asset Management AG, Seestrasse 16 , CH - 8700 Kusnacht

Fund documents StarCapital Equity Value plus, StarCapital Multi Income, StarCapital Strategy 1 and StarCapital Dynamic Bonds.

Prospectus, the key investor information document ("KID"), the management regulations and the semi-annual and annual report are available free of charge in German from Bellevue Asset Management (Deutschland) GmbH, your advisor or intermediary, the paying agents, the relevant custodian bank or from the management company IPConcept (Luxembourg) S.A. (société anonyme), 4, rue Thomas Edison, L-1445 Luxembourg, Luxembourg, https://www.ipconcept.com. For information on opportunities and risks as well as tax information, please refer to the current detailed sales prospectus. Further information on investor rights can be found on the Management Company's website (https://www.ipconcept.com). The management company may decide to cancel the arrangements it has made for the distribution of the units of its collective investment undertakings in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU.

Fund documents Bellevue Option Premium fund

Prospectus, the key investor information document ("KID"), the management regulations and the semi-annual and annual reports are available free of charge in German from Bellevue Asset Management (Deutschland) GmbH, your advisor or intermediary, the paying agents, the responsible depositary (UBS Europe SE, Bockenheimer Landstrasse 2-4, D-60306 Frankfurt am Main) or from the management company Universal-Investment-Gesellschaft mbH, Theodor-Heuss-Allee 70, D-60486 Frankfurt am Main, https://www.universal-investment.com. For information on opportunities and risks as well as tax information, please refer to the current detailed sales prospectus. Further information on investor rights can be found on the Management Company's website (https://www.universal-investment.com). The management company may decide to cancel the arrangements it has made for the distribution of the units of its collective investment undertakings in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU.

 Fund documents StarCapital Premium Bonds plus  

Prospectus, the key investor information document ("KID"), the management regulations and the semi-annual and annual reports. These can be obtained free of charge in German from Bellevue Asset Management (Deutschland) GmbH, your advisor or intermediary, the paying agents, the responsible depositary (UBS Europe SE, Bockenheimer Landstrasse 2-4, D-60306 Frankfurt am Main) or from the management company Donner & Reuschel AG, Ballindamm 27, 20095 Hamburg, https://www.donner-reuschel.de. For information on opportunities and risks as well as tax information, please refer to the current detailed sales prospectus. Further information on investor rights can be found on the Management Company's website (https://www.universal-investment.com). The management company may decide to cancel the arrangements it has made for the distribution of the units of its collective investment undertakings in accordance with Article 93a of Directive 2009/65/EC and Article 32a of Directive 2011/61/EU.

Data protection

By accessing this website you state that you agree with the data protection statement. If you do not agree with this statement you should refrain from accessing any further pages of this website. This statement may be updated at any time. We therefore recommend that you check this statement regularly.

Confirmation

By clicking on "Accept", you confirm that you agree to the legal provisions. 

With the coronavirus pandemic behind us, the healthcare sector has fallen off many investors’ radar screens. “Unjustly so, in view of the quickening pace of medical progress in many therapeutic areas,” says Dr. Cyrill Zimmermann, Head of Healthcare Funds & Mandates at Bellevue Asset Management.

Healthcare – a buying opportunity for contrarian investors

With the coronavirus pandemic behind us, the healthcare sector has fallen off many investors’ radar screens. “Unjustly so, in view of the quickening pace of medical progress in many therapeutic areas,” says Dr. Cyrill Zimmermann, Head of Healthcare Funds & Mandates at Bellevue Asset Management.
09.08.2023 - Cyrill Zimmermann

2023 has been a disappointing year for investors in healthcare equities. The MSCI World Healthcare Index, the bellwether equity index for the healthcare industry, is hardly any higher now than it was at the beginning of the year. Meanwhile the S&P 500 has gained 17% year-to-date. Although that gain has largely been fueled by the sizzling performance of seven giant tech stocks, it can't be denied that most investors are sticking to the sidelines when it comes investing in the healthcare space.

We believe there are two reasons why so many investors have decided to stay away from healthcare stocks: Central-bank rate hikes in response to rampant inflation have had the greatest impact on the valuations of companies that are not yet generating a steady flow of income and that are dependent on external financing to stay in business. These are often biotechnology companies and firms that are developing tech-related applications such as sensors or measuring devices for digital health solutions. Mega caps in the pharmaceutical space, true to their defensive reputation, have been affected less by the aforementioned developments. The other reason is psychological in nature. The big breakthrough that was achieved with the development of COVID-19 vaccines increased public awareness of how a new therapeutic approach can play a critical role in overcoming problems that affect society as a whole. The flip side of the coin is that as the coronavirus pandemic faded in the rear-view mirror, investors turned away from the sector in droves.

Artificial intelligence is a theme that has attracted plenty of interest from investors lately. AI also happens to be an increasingly important tool in drug discovery and development processes, and in the medical technology industry. The healthcare sector’s increasingly impressive innovation power has attracted far fewer headlines, but it is equal in significance. This is evident, for example, in drug development processes. In the United States, which remains the world's largest market for healthcare, there have been 29 new drug approvals so far this year to the beginning of August. The chances are good, then, that more than 40 novel drugs will be granted marketing approval from the FDA in 2023, as in most years. Recent developments in the therapeutic areas of diabetes, cancer and Alzheimer's are particularly promising.

Alarming increase in the number of people with diabetes
Many of today's novel therapeutic approaches are targeting common diseases that are increasing in prevalence globally. Diabetes is an immense economic burden in the face of spiraling healthcare costs. The numbers speak for themselves: There are 500 million people living with diabetes worldwide, and not only in Western industrialized nations but increasingly in newly industrialized countries such as China, India and Saudi Arabia, a country where one in three adults has diabetes. The global cost of diabetes now stands at USD 1 trn, which corresponds to some 10% of global annual healthcare expenditures. And this astronomical sum does not even take the typical comorbidities and complications associated with diabetes such as heart attacks, strokes, renal failure and vision loss into account. The more than 300% increase in the economic burden over the last 15 years is alarming. It goes without saying that the market for medical devices that monitor and regulate blood sugar levels and insulin intake with increasing precision is huge and growing fast. Glucose monitoring devices have been developed that can send information via sensors in the skin to a receiver every five minutes and use algorithms to calculate the exact amount of insulin that must be delivered by an integrated insulin pump. New drugs are also available for patients with diabetes and obesity that should make diabetes an increasingly manageable condition.

Obesity is one of the main causes of diabetes. 13% of the US population had a body mass index of more than 30 in 1980. By 2020, this percentage had risen to 42%. On the medicine front, we are currently witnessing some very exciting developments. First and foremost, Novo Nordisk and Eli Lilly have developed medicines that – in simple terms – reduce feelings of hunger and help patients lose 15% to 20% of their body weight after a few months of treatment. The market potential is correspondingly huge – global sales in 2030 are expected to total USD 44 bn.

Taking the fight against cancer to a new level
The second major global therapeutic area is oncology. Twenty million new cases of cancer are diagnosed worldwide every year. The national cost of cancer care in the US alone amounts to USD 200 bn. Instead of chemotherapy, novel approaches are being pursued, such as antibodies that attack tumors on two different fronts, or new types of immunotherapies that are designed to activate the body’s own immune system to make it better and faster at identifying and eliminating tumor cells. Lung cancer and colorectal cancer are two types of cancer whose prevalence is on the rise worldwide due to poor diet and cigarette smoking. In addition to new drugs, an increasing number of cancer diagnostic methods have entered the market that are able detect the development of cancer at an early stage.

Encouraging developments in Alzheimer's research
The third major challenge is the growing prevalence of neurodegenerative diseases as a result of global demographic aging. Alzheimer's disease, by far the most common form of dementia, figures most prominently here. After decades of clinical failures in Alzheimer’s research, regulators approved Leqembi, a drug developed by Biogen/Eisai that is a disease-modifying therapy that effectively slows the progression of the disease. In clinical testing it delayed disease progression by nearly three years on average and it slowed the rate of cognitive decline by 27% compared with placebo. A drug from rival Eli Lilly is now being reviewed by the FDA too. These initial breakthroughs will likely unlock even more spending on Alzheimer's research worldwide in the coming years.

Healthcare stocks attractively valued
A quick glance at the valuation multiples for the MSCI World and for the healthcare sector (MSCI World Healthcare) reveals that the price/earnings ratios for both indexes are about the same, around 17 times forward earnings. Looking at profit growth rates, though, the comparison shifts in favor of healthcare. The price/earnings to growth ratio (PEG) of 1.9 for the healthcare sector is much more attractive than the total market's PEG of 2.6. Biotech stocks look particularly cheap with a P/E ratio of 14 and a PEG of 1.1. Investors with a countercyclical approach can now buy the sector at historically low valuations. Its full return potential will be unlocked once the broader investment community, attracted by the flashing momentum indicators, discovers the healthcare sector again.

 

  • Dr. Cyrill Zimmermann

    Dr. Cyrill Zimmermann

    Dr. Cyrill Zimmermann is Head of Healthcare Funds & Mandates and a member of the Executive Board of Bellevue Asset Management. He founded Adamant Biomedical Investments in 2001 and was the investment boutique’s CEO until its acquisition by Bellevue in 2014. Cyrill Zimmermann holds a Ph.D. in economics from the University of Zurich.